The Antibody Drug Conjugates Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Antibody Drug Conjugates Market?
The global market for antibody drug conjugates has seen significant growth recently. The market size was $13.57 billion in 2024 and is predicted to reach $16.66 billion in 2025, representing a Compound Annual Growth Rate (CAGR) of 22.7%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Antibody Drug Conjugates Industry?
The Antibody Drug Conjugates Global Market is projected to reach $38.39 billion in 2029, with a compound annual growth rate (CAGR) of 23.2%.
Download Your Free Sample of the 2025 Antibody Drug Conjugates Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Antibody Drug Conjugates Market?
The key drivers in the antibody drug conjugates market are:
• Next generation Antibody Drug Conjugates (ADCs) development
• Expanding indications for Antibody Drug Conjugates
• Increasing focus on personalized medicine
• Rising investment in precision medicine and increasing healthcare awareness
Global Market Segmentation: Identifying Major Antibody Drug Conjugates Industry Segments
The antibody drug conjugates market covered in this report is segmented –
1) By Type: Monoclonal Antibodies, Linker, Drug/Toxin, Other Types
2) By Product: Adcertis, Kadcyla, Other Products
3) By Technology: Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Other Technology
4) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Applications
5) By End User: Hospital, Clinics, Other End Users
Pre-order the 2025 Antibody Drug Conjugates Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Antibody Drug Conjugates Market?
The key trends in the antibody drug conjugates market are:
• Next generation Antibody Drug Conjugates (ADCs) are expected to drive.
• Growing emphasis on personalized medicine is a significant trend.
• Higher investments in precision medicine are shaping the market's future.
• Developments in conjugation technologies will play a crucial role in advancing ADCs.
Who Are the Top Competitors & Leading Players in the Antibody Drug Conjugates Market?
Major companies in the antibody drug conjugates market are:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.
• AstraZeneca plc
• Takeda Pharmaceutical Company Limited
• Millennium Pharmaceuticals Inc.
• Gilead Sciences Inc.
• Daiichi Sankyo Company Limited
• Sorrento Therapeutics Inc.
• Astellas Pharma Inc.
• Zydus Lifesciences Limited
• Seagen Inc.
• Synthon BV
• Genentech Inc.
• ImmunoGen Inc.
• Nordic Nanovector ASA
• ADC Therapeutics SA
• Immunomedics Inc.
• Mersana Therapeutics Inc.
• Heidelberg Pharma AG
• Celldex Therapeutics Inc.
• Oxford BioTherapeutics
• Concortis Biotherapeutics Corp.
• Antikor BioPharma Ltd.
• Eisai Co. Ltd.
• Merck KGaA
Regional Dominance: Which Area Leads the Global Template Market?
North America was the largest region in the antibody-drug conjugates (ADCs) market in 2024
